Initiate UPLIFT single-arm registration strategy for XMT-1536
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- April 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“UPLIFT single-arm registration strategy studying XMT-1536 in platinum-resistant ovarian cancer expected to initiate in first quarter of 2021”
What we found
Evidence strength A What the grades mean
The company initiated the UPLIFT registration strategy in April 2021, which occurred after the first quarter 2021 deadline.
-
A Mersana Therapeutics, Inc. 8-K filed 2021-05-10
“In April 2021, the Company announced the initiation of patient dosing in UPLIFT” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- UPLIFT single-arm registration strategy
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Mersana Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C442836-021018 · Corrections policy